Synaptogenix (NASDAQ:TAOX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on TAOX
Synaptogenix Stock Down 10.4%
Synaptogenix (NASDAQ:TAOX – Get Free Report) last released its earnings results on Monday, November 16th. The company reported $0.38 earnings per share for the quarter. Synaptogenix had a negative net margin of 768.22% and a negative return on equity of 68.93%. The company had revenue of $0.25 million for the quarter.
Synaptogenix Company Profile
Synaptogenix was a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and disorders involving impaired cognitive function. The company’s research centered on therapies intended to support synaptic function. Its lead investigational drug candidate was bryostatin-1, which it studied as a potential treatment for Alzheimer’s disease. The company also explored its approach in other conditions associated with cognitive impairment. Bryostatin-1 was investigational, not an approved medicine.
Recommended Stories
- Five stocks we like better than Synaptogenix
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
